Addex Therapeutics Ltd (ADXN)
8.785
-0.04
(-0.40%)
USD |
NASDAQ |
May 23, 16:00
Addex Therapeutics Cash from Investing (Quarterly): -0.0012M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0012M |
| September 30, 2023 | -0.0009M |
| June 30, 2023 | -0.0029M |
| March 31, 2023 | -0.0027M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.0031M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.0267M |
| September 30, 2021 | -0.0005M |
| Date | Value |
|---|---|
| June 30, 2021 | -0.0024M |
| March 31, 2021 | -0.0035M |
| December 31, 2020 | -0.0511M |
| September 30, 2020 | -0.0013M |
| June 30, 2020 | -0.0022M |
| March 31, 2020 | -0.0088M |
| December 31, 2019 | -0.0174M |
| September 30, 2019 | -0.0037M |
| June 30, 2019 | -0.0036M |
| March 31, 2019 | -0.0188M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-0.0511M
Minimum
Dec 2020
0.0031M
Maximum
Sep 2022
-0.0066M
Average
-0.0024M
Median
Jun 2021
Cash from Investing (Quarterly) Benchmarks
| AC Immune SA | -26.96M |
| CRISPR Therapeutics AG | -97.80M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 20.15M |
| MoonLake Immunotherapeutics | -28.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.5563M |
| Cash from Financing (Quarterly) | -0.1643M |
| Free Cash Flow | -8.908M |
| Free Cash Flow Per Share (Quarterly) | -0.775 |
| Free Cash Flow to Equity (Quarterly) | -0.5575M |
| Free Cash Flow to Firm (Quarterly) | -0.5575M |
| Free Cash Flow Yield | -163.2% |